2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162656
    DHFR-IN-19 41927-06-4 98%
    DHFR-IN-19 (Compound 2g) is a selective inhibitor for TbDHFR with Ki of 9 nM. DHFR-IN-19 exhibits antiparasitic activity against Trypanosoma brucei with an EC50 of 14.5 μM.
    DHFR-IN-19
  • HY-162672
    Antibacterial agent 231 98%
    Antibacterial agent 231 (derivative 8) is an antimicrobial agent against multidrug-resistant Helicobacter pylori (H. pylori) with a minimum inhibitory concentration of 0.25–0.5 μg/mL. Antibacterial agent 231 directly targets the protein transposase subunit SecA and the outer membrane protein assembly factor BamD to inhibit the trafficking and assembly of bacterial outer membrane proteins (OMPs). Antibacterial agent 231 can be used to study the effects of antibiotic treatment on intestinal microbial balance.
    Antibacterial agent 231
  • HY-162674
    MERS-CoV-IN-2 3049658-41-2 98%
    MERS-CoV-IN-2 (compound 3c) is a MERS-CoV 3CLpro inhibitor (IC50=17nM). MERS-CoV-IN-2 inhibits the activity of the 3CLpro enzyme by binding to the active site of the enzyme, specifically the S4 subsite, thereby exhibiting antiviral activity against SARS-CoV-2 and MERS-CoV.
    MERS-CoV-IN-2
  • HY-162707
    RA-0002323-01 98%
    RA-0002323-01 is an antiviral agent targeting viral helicase and is an active compound from Heli-SMACC, a collection of small molecules targeting helicase.
    RA-0002323-01
  • HY-162719
    RH12 98%
    RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC50 is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC50 of 17.5 nM.
    RH12
  • HY-16278R
    Pradigastat (Standard) 956136-95-1 98%
    Pradigastat (Standard) is the analytical standard of Pradigastat. This product is intended for research and analytical applications. Pradigastat (LCQ-908) is a selective and orally effective diacylglyceryl acyltransferase 1 (DGAT1) inhibitor with IC50 at 0.157 µM. Pradigastat is primarily used to study diseases associated with abnormal triglyceride metabolism. Pradigastat has anti-obesity and anti-diabetic effects. Pradigastat inhibited BCRP, OATP1B1, OATP1B3 and OAT3 activities with IC50 of 5 µM, 1.66µM, 3.34µM and 0.973µM, respectively. In addition, Pradigastat has antiviral activity and can inhibit hepatitis C virus replication in vitro.
    Pradigastat (Standard)
  • HY-162818
    Antibacterial agent 237 98%
    Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models.
    Antibacterial agent 237
  • HY-162884
    β-Glucuronidase-IN-4 2208619-76-3 98%
    EcGUS-IN-1 (Compound E-9) is a non-competitive β-glucuronidase inhibitor, with an IC50 of 2.68 μM and a Ki value of 1.64 μM. EcGUS-IN-1 can improve gastrointestinal adverse events (GIAE) caused by Escherichia coli infection by inhibiting E. coli β-glucuronidase activity.
    β-Glucuronidase-IN-4
  • HY-162899
    DXR-IN-3 1465907-72-5 98%
    DXR-IN-3 is a DXR inhibitor that specifically targets Toxoplasma gondii. DXR-IN-3 shows in vitro activity against the TgDXR enzyme, with an IC50 value of 0.62 μM and a Ki value of 0.19 μM. DXR-IN-3 can inhibit the proliferation of Toxoplasma, with an IC50 value of 5.46 μM.
    DXR-IN-3
  • HY-162957
    LasR-IN-5 98%
    LasR-IN-5 (compound 3C) is a LasR antagonist with an IC50 of 1.37 μM, demonstrating a 77% inhibition of biofilm formation in Pseudomonas aeruginosa. LasR-IN-5 also exhibits quorum sensing (QS) inhibition activity and has potential applications in Pseudomonas aeruginosa infection research.
    LasR-IN-5
  • HY-163015
    RNA polymerase-IN-1 2447106-74-1 98%
    RNA polymerase-IN-1 (compound 4) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-1 inhibits CYP isozymes.
    RNA polymerase-IN-1
  • HY-163016
    RNA polymerase-IN-2 2447106-79-6 98%
    RNA polymerase-IN-2 (compound 5) is s DNA-dependent RNA polymerase inhibitor. RNA polymerase-IN-2 inhibits CYP isozymes.
    RNA polymerase-IN-2
  • HY-163029
    CTSL/B-IN-1 98%
    CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC50s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research.
    CTSL/B-IN-1
  • HY-163030
    LasB-IN-1 98%
    LasB-IN-1 (compound 5f) is a potent and orally active inhibitor of LasB (IC50 = 8.7 μM). LasB-IN-1 effectively attenuates elastase production and biofilm formation by P. aeruginosa while alleviating the inflammatory response through downregulating MAPK and NF-κB pathways. LasB-IN-1 is potential to be a novel anti-infective candidate against drug-resistant infections.
    LasB-IN-1
  • HY-163033
    Antitubercular agent-42 98%
    Antitubercular agent-42(19) is a selective fatty acyl-AMP ligase (FAAL) inhibitor (MIC90 = 1.4 µg/mL for M. tuberculosis H37Rv). Antitubercular agent-42 shows antitubercular activity.
    Antitubercular agent-42
  • HY-163060
    Metronidazole phosphate disodium 111682-58-7 98%
    Metronidazole phosphate disodium is a water-soluble prodrug for parenteral solutions of Metronidazole (HY-B0318). Metronidazole phosphate disodium is an antibiotic and can be used for the research of anaerobic infections.
    Metronidazole phosphate disodium
  • HY-163063
    Antimalarial agent 34 98%
    Antimalarial agent 34 is a modest PfARK1/3 inhibitor and shows potent antiplasmodial activity (EC50 = 0.16 μM).
    Antimalarial agent 34
  • HY-163067
    SARS-CoV-2-IN-71 98%
    SARS-CoV-2-IN-71 (compound 8h) is a potent inhibitor of SARS-CoV-2. SARS-CoV-2-IN-71 inhibits coronavirus replication at multiple stages. SARS-CoV-2-IN-71 displays anti-coronaviral effect by simultaneously acting on 3CLpro and TMPRSS2.
    SARS-CoV-2-IN-71
  • HY-163069
    Antitubercular agent-43 98%
    Antitubercular agent-43 (compound A11) is an orally active and potent antitubercular agent. Antitubercular agent-43 shows highly metabolic stability against human and mouse cytochrome P450 enzymes. Antitubercular agent-43 exhibits bactericidal efficacy in acute TB infection mouse model.
    Antitubercular agent-43
  • HY-163073
    Anti-MRSA agent 9 98%
    Anti-MRSA agent 9 (compound 39) shows antibacterial effects against clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 1 μg/ml. Anti-MRSA agent 9 also shows anti-MRSA efficacy in vivo.
    Anti-MRSA agent 9
Cat. No. Product Name / Synonyms Application Reactivity